Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets

Alzheimer's disease (AD) is characterized by an accumulation of β-amyloid (Aβ42) accompanied by brain atrophy and cognitive decline. Several recent studies have shown that Aβ42 accumulation is associated with gray matter (GM) changes prior to the development of cognitive impairment, in the so-c...

Full description

Saved in:
Bibliographic Details
Published in:NeuroImage clinical 2018-01, Vol.19, p.190-201
Main Authors: Falcon, Carles, Tucholka, Alan, Monté-Rubio, Gemma C., Cacciaglia, Raffaele, Operto, Grégory, Rami, Lorena, Gispert, Juan Domingo, Molinuevo, José Luis
Format: Article
Language:English
Subjects:
Aged
Alzheimer Disease - cerebrospinal fluid
Alzheimer Disease - diagnostic imaging
Alzheimer Disease - pathology
Alzheimer's disease
Amyloid beta-Peptides - cerebrospinal fluid
Atrophy - cerebrospinal fluid
Atrophy - diagnostic imaging
Atrophy - pathology
Biomarkers - cerebrospinal fluid
Brain - diagnostic imaging
Brain - pathology
CSF biomarkers
Disease Progression
Female
Humans
Longitudinal Studies
Longitudinal VBM
Magnetic Resonance Imaging
Male
Middle Aged
Neuropsychological Tests
Peptide Fragments - cerebrospinal fluid
Preclinical Alzheimer's disease
Regular
tau Proteins - cerebrospinal fluid
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer's disease (AD) is characterized by an accumulation of β-amyloid (Aβ42) accompanied by brain atrophy and cognitive decline. Several recent studies have shown that Aβ42 accumulation is associated with gray matter (GM) changes prior to the development of cognitive impairment, in the so-called preclinical stage of the AD (pre-AD). It also has been proved that the GM atrophy profile is not linear, both in normal ageing but, especially, on AD. However, several other factors may influence this association and may have an impact on the generalization of results from different samples. In this work, we estimate differences in rates of GM volume change in cognitively healthy elders in association with baseline core cerebrospinal fluid (CSF) AD biomarkers, and assess to what these differences are sample dependent. We report the dependence of atrophy rates, measured in a two-year interval, on Aβ42, computed both over continuous and categorical values of Aβ42, at voxel-level (p 
ISSN:2213-1582
2213-1582
DOI:10.1016/j.nicl.2018.04.016